Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer

Oncology

Volumn 76, Issue 3, 2009, Pages 151-156

  Arkenau, Hendrik Tobias ^a   Brunetto, Andre T ^b   Barriuso, Jorge ^b   Olmos, David ^b   Eaton, David ^b   De Bono, Johann ^b   Judson, Ian ^b   Kaye, Stan ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Advanced colorectal cancer; Outcome; Phase I trial; Survival

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; PANITUMUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 58349112979     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000195884     Document Type: Article

References (24)

1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(suppl 8):S4-S66.
2. Quinn M, Babb P, Brock A, Jones J: Cancer Trends in England and Wales 1950-1999. London, The Stationery Office, 2001.
3. Goldberg RM: Advances in the treatment of metastatic colorectal cancer. Oncologist 2005;10(suppl 3):40-48.
4. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
5. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
6. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
7. Tournigand C, André T, Achille E, et al: FOLFIRI followed FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
9. Cassidy, Clarke S, Diaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-2012.
10. Van Cutsem E, Nowacki M, Lang I, et al: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (MCRC): the CRYSTAL trial (abstract 4000). J Clin Oncol 2007;25:164s.
11. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
12. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
13. Chong G, Dickson JL, Cunningham D, et al: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005;93:510-514.
14. Therasse P, Arbruck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
15. Arkenau HT, Olmos D, Ang JE, et al: Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 2008;98:1029-1033.
16. Arkenau HT, Olmos D, Ang JE, et al: 90-Days mortality rate within the context of a phase I trial: how should we identify patients who should not go on trial? Eur J Cancer 2008, E-pub ahead of print.
17. Arkenau HT, Barriuso J, Olmos D: Prospective validation of a prognostic score for patients treated within the context of phase I trial (abstract 2508). ASCO 2008.
18. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Ass 1958;53:457-481.
19. Cox DR: Regression models and life tables. J Roy Stat Soc (B) 1972;34:187-202.
20. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
21. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
22. Saltz LB, Rosen LS, Marshall JL, et al: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007;25:4793-4799.
23. Meropol N, Weinfurt KP, Burnett CB, et al: Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patients communication. J Clin Oncol 2003;21:2589-2596.
24. Hamilton SR: Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol 2008;21(suppl 2):S23-S30.